Replies to post #392079 on Innovation Pharmaceuticals Inc (IPIX)

[Hungry_Ghost]

GREAT POST !!!! The government scientists should be tested for *B426* addiction. They can’t stop coming back for more and more testing. Now they want to test against Monkeypox.
Love all the free testing.
Something BIG is going to come from the hard work of all these researchers.
Great job Leo for maneuvering *B426* into position to reach the next level. Get a deal done to cap off 2 plus years of hard work.

*B426* You will wish you bought more….

[CallMeCrazy]

Why NIAID Is Spending Money To Test B-Antiviral

NIAID PANDEMIC PREPAREDNESS PLAN
December 2021

Background

The NIAID pandemic preparedness plan focuses predominantly on viruses that could cause epidemics or pandemics and prioritizes research on prototype-pathogens, representative pathogens from viral families known to infect humans, and high-priority pathogens most likely to threaten human health.
Research and development will encompass preclinical research, translational, and early phase clinical studies to evaluate candidate medical countermeasures, such as vaccines, therapeutics, and monoclonal antibodies

Introduction

To prepare for future public health emergencies caused by infectious diseases, NIAID has developed a Pandemic Preparedness Plan that leverages its broad research portfolio, long-standing expertise in product development, capacity to
engage both domestic and international partners, and flexible infrastructure. While it is recognized that pathogens other than viruses could lead to public health emergencies, the NIAID Pandemic Preparedness Plan focuses on viruses that could cause epidemics or pandemics.

Therapeutics
NIAID will continue to support basic, translational, and clinical research efforts to identify promising targets for intervention and generate novel therapeutics that are both pathogen-specific and have broad-spectrum activity. Leveraging earlier successful partnerships (as for HIV drug development) and continuing the collaborative interactions that were established in response to the COVID-19 pandemic, NIAID will engage pharmaceutical companies to share libraries, medicinal chemistry, and drug development expertise to accelerate internal efforts to ensure the most promising drug candidates progress rapidly into clinical use.

Small Molecule/Antivirals
The Pandemic Preparedness Plan will respond to the pressing need for safe and effective therapeutics by building sustainable platforms for targeted drug discovery through the development of small molecules and antivirals that may be useful against a wide range or class of pathogens of concern. NIAID will evaluate and advance new drug candidates to the stage of being late Phase 2-ready. One existing program through which NIAID will develop safe and effective antivirals is the Antiviral Program for Pandemics (APP). The APP will focus on antivirals that directly act against viral targets, specifically for RNA viruses. Antivirals of interest will have broad use in the outpatient setting, reducing viral burden in the early stages of infection.

As part of the APP, NIAID will establish Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern. The centers will initially focus on novel, oral antivirals for SARS-CoV-2 and other coronaviruses and will expand to other pathogens of pandemic concern in future years.

https://www.niaid.nih.gov/sites/default/files/pandemic-preparedness-plan.pdf

No need to argue with naysayers, the only measure one need to look at in determining if B-Antiviral (B-AV) has any value is the answer to the question: Is the NIAID still funding the testing/development of B as an anti-viral? After 2-and-a-half years, the answer for B-AV is YES.
In accordance with their viral disease fighting priorities, NIAD will fund a promising candidate (B-AV) through phase 2A clinical testing. I think it's a good presumption that after B-AV jumps through all of NIAID's "hoops" IPIX will have little trouble, if any, finding a partner to finance a phase 3 on agreeable terms. Afterall, upon FDA approval/authorization, the U.S. government will be the first customer, spending tens of millions of dollars for B-AV to disseminate to the public or to stockpile for future emergency use.

Strategic National Stockpile (SNS)

The SNS is a network of strategically located repositories located throughout the United States that houses a vast inventory of antibiotics, antitoxins, antiviral drugs, vaccines, medical supplies and materials, and other pharmaceuticals.

https://remm.hhs.gov/sns.htm#kinds

"The U.S. government is, essentially, in control of IPIX's Brilacidin Antiviral Program" and boy am I glad they are.